ERBB2 and breast neoplasm: There are several ADC therapies which are in clinical trials as novel agents or an improvement of existing therapies that have shown efficacy mostly in metastatic HER2-enriched breast tumors including SYD985, ZRC-3256, TAA013 all in phase III trials; MRG002 in phase II trials; A166 and SHR-A1201 in phase I/II trials; and ALT-P7, ZW49, Bi-CON-02 and B003 in phase I trials (Najjar et al., 2022; Yu et al., 2022).